You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
先聲藥業(02096.HK)向Almirall授予治療自身免疫疾病藥物海外開發權
阿思達克 09-29 08:21
先聲藥業(02096.HK)公布,集團授予國際生物製藥公司Almirall在大中華以外地區開發和商業化自身免疫領域候選藥物SIM0278的獨家權益。 根據該協議條款,集團將收取Almirall1,500萬美元首付款,並基於多個適應症的可能成果收取最多4.92億美元開發和商業里程碑付款(包括部分銷售里程碑);另有基於該產品未來在協議地區銷售情況的低雙位數百分比分級提成。集團將保留該產品在大中華地區的所有權益。 SIM0278是基於集團自有蛋白質工程技術平台開發的一種調節性T細胞(Treg)偏好型IL2融合蛋白(IL-2muFc),這一即將遞交新藥臨床試驗申請的皮下注射產品有望開發用於治療多種自身免疫疾病。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account